Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 20, 2018
Pharmacy Choice - News - Pharmaceutical Development - July 20, 2018

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

7/20/18 - INTERIM REPORT 1 APRIL- 30 JUNE 2018
"Our business in Europe is growing, driven by Germany which now starts to show signs of real commercial progress. In parallel, we have developed a robust clinical strategy targeting a US FDA approval and have taken a significant step in US by the filing of our IDE application ", says Pl Ryfors, CEO Episurf Medical. Gross order intake increased
7/20/18 - Investigators at New York Medical College Release New Data on Neuroblastomas (A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF,...
According to news reporting from Valhalla, New York, by NewsRx journalists, research stated, "A phase 3 randomized study demonstrated significantly improved outcome by adding immunotherapy with ch14.18 antibody to isotretinoin as post-consolidation therapy for high-risk neuroblastoma. Funders for this research include National Institutes of Health,
7/20/18 - Sobi? strengthens inflammation franchise by acquiring global rights for emapalumab from Novimmune
Sobi? strengthens inflammation franchise by acquiring global rights for emapalumab from Novimmune. Swedish Orphan Biovitrum AB, an international biopharmaceutical company dedicated to rare diseases, and Novimmune SA have entered into an exclusive licence agreement for the perpetual global rights to emapalumab, a late-stage orphan drug candidate f
7/20/18 - WuXi STA and Antengene Sign Development and Manufacturing Agreement
STA Pharmaceutical Co., Ltd.,- a subsidiary of WuXi AppTec- and Antengene Corporation, a biopharmaceutical company, recently announced a strategic partnership for the CMC development and manufacturing of innovative oncology drugs. Under the terms of the collaboration, WuXi STA will provide Antengene an integrated solution in process R&D and manuf
7/19/18 - 2 Day Seminar: FDA Approval Process for Medical Devices
The " FDA Approval Process for Medical Devices" conference has been added to ResearchAndMarkets.com' s offering. This seminar will provide a solid foundation in the approval and clearance processes for medical devices in the United States. Participants will gain an understanding of the underlying legal and regulatory requirements and the general co
7/19/18 - 2 Day Seminar: FDA Approval Process for Medical Devices - ResearchAndMarkets.com
The " FDA Approval Process for Medical Devices" conference has been added to ResearchAndMarkets.com' s offering. This seminar will provide a solid foundation in the approval and clearance processes for medical devices in the United States. Participants will gain an understanding of the underlying legal and regulatory requirements and the general co
7/19/18 - Abivax Completes Dosing in Phase 2a Proof-of-Concept Clinical Trial of ABX464 in Ulcerative Colitis (ABX464-101)
ABIVAX, a biotechnology company harnessing the immune system to develop a functional cure for HIV, as well as treatments for inflammatory/autoimmune diseases and cancer, today announced the completion of dosing in its Phase 2 a clinical trial ABX464-101 in 32 patients with moderate-to-severe ulcerative colitis. Hartmut Ehrlich, M.D., Chief Executiv
7/19/18 - ACADIA Pharmaceuticals Announces Appointment of Austin D. Kim as Executive Vice President, General Counsel and Secretary
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that Austin D. Kim has joined ACADIA as Executive Vice President, General Counsel and Secretary. Austin D. Kim, Executive Vice President
7/19/18 - Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials for Abicipar pegol 8 and 12-week Regimens for the Treatment in Patients with Neovascular Age-Related Macular Degeneration
Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials for Abicipar pegol 8 and 12- week Regimens for the Treatment in Patients with Neovascular Age-Related Macular Degeneration. Abicipar, the first and only anti-VEGF to maintain stable vision in greater than 91 percent of patients on a fixed 12- week regimen, achieved the pr
7/19/18 - Alligator Bioscience Submits Application to Start Clinical Phase I Study in Cancer Patients with ATOR-1015, a Unique CTLA-4 and OX40 Binding Antibody
Alligator Bioscience, a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, today announced that the company has submitted a clinical trial authorization application to the relevant regulatory authorities to start a phase I study of its wholly-owned bispecific drug candidate ATOR-1015.
7/19/18 - Alopexx Vaccine Reports Successful Maternal Immunization Protecting Foals from an Intracellular Equine Pathogen Similar to Tuberculosis
These results, which were published by investigators at Harvard Medical School, Brigham and Women's Hospital and Texas A&M College of Veterinary Medicine in the July 19, 2018 issue of PLOS Pathogens describe the ability of an antibody-inducing vaccine to provide protective immunity against intracellular pathogens, further supporting development of
7/19/18 - Altasciences Participates in Clinical Trial for Type 1 Diabetes Mellitus [Syrian Arab News Agency]
Altasciences is pleased to have partnered with Xeris Pharmaceuticals, a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables, on a randomized, controlled, single blind, two-way crossover study to evaluate the efficacy and safety of their...
7/19/18 - Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency
By a News Reporter-Staff News Editor at Gene Therapy Weekly Arrowhead Pharmaceuticals Inc. announced that the European Medicines Agency Committee for Orphan Medicinal Products issued a positive opinion on Arrowhead's application for orphan designation of its RNAi candidate, ARO-AAT, for the treatment of congenital alpha-1 antitrypsin deficiency.
7/19/18 - Asana BioSciences Initiates Phase 2b Study of ASN002 in Patients with Moderate-to-Severe Atopic Dermatitis (RADIANT)
Asana BioSciences, a clinical stage biopharmaceutical company focused on discovery and development of novel targeted investigational medicines in Immunology/Inflammation and Oncology, today announced initiation of a Phase 2 b study of ASN002, an oral JAK/SYK inhibitor, in patients with moderate-to-severe atopic dermatitis. Robert Bissonnette, the..
7/19/18 - Atossa Genetics Announces Intraductal Microcatheter ImmunoOncology Pre-Clinical Program [Sport360]
Atossa Genetics Inc., a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it is advancing its intraductal microcatheter immunotherapy program with pre-clinical studies being conducted by Translational Drug Development, LLC.
7/19/18 - Atossa Genetics Announces Intraductal Microcatheter ImmunoOncology Pre-Clinical Program [Sudan Tribune]
-Atossa Genetics Inc., a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it is advancing its intraductal microcatheter immunotherapy program with pre-clinical studies being conducted by Translational Drug Development, LLC.
7/19/18 - Biological Implants Market 2018 Global Trend, Segmentation And Opportunities Forecast To 2023
Biological Implants- Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021. Wiseguyreports.Com Adds "Biological Implants- Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021" To Its Research Database. The total biological implants market is analyzed by tissue/muscle; origin, and mode o
7/19/18 - Cassiopea Announces Top Line Positive Proof of Concept Phase II Results for CB-06-02 Immune Modulator in Treating Genital Warts
Cassiopea Announces Top Line Positive Proof of Concept Phase II Results for CB-06-02 Immune Modulator in Treating Genital Warts. Lainate, Italy- 19 July 2018- Cassiopea SpA, a clinical-stage pharmaceutical company developing and commercializing innovative medical dermatology products, today announced that the proof of concept phase II clinical tria
7/19/18 - Catalyst Biosciences Announces Positive Interim Data from a Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors [T-break Tech (Middle East)]
-Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced interim data from its Phase 2/ 3 study of subcutaneous prophylactic Factor VIIa variant marzeptacog alfa being developed for the treatment of hemophilia A or B with inhibitors in a poster..
7/19/18 - Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients [Sport360]
Cellectar Biosciences, a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces positive interim results from the company`s Phase 2 clinical trial for its lead product candidate CLR 131, in patients with diffuse large B-cell lymphoma.
7/19/18 - Circulating Tumor Cells (CTC) Technologies Market 2018 Global Trend, Segmentation And Opportunities Forecast To 2023
Circulating Tumor Cells Technologies- Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021. Major Contract Research Organizations, Research Institutes and Universities serving the CTC market are also covered in the corporate directory section of this report. A global perspective is presented along with regional analy
7/19/18 - DGAP-News: EVOTEC RECEIVES MILESTONE PAYMENT FOR START OF PHASE II TRIAL IN ITS MULTI-TARGET ALLIANCE WITH BAYER (english)
EVOTEC RECEIVES MILESTONE PAYMENT FOR START OF PHASE II TRIAL IN ITS MULTI-TARGET ALLIANCE WITH BAYER ^ DGAP-News: Evotec AG/ Key word: Miscellaneous EVOTEC RECEIVES MILESTONE PAYMENT FOR START OF PHASE II TRIAL IN ITS MULTI-TARGET ALLIANCE WITH BAYER 19.07. 2018/ 07:00 The issuer is solely responsible for the content of this announcement.-
7/19/18 - E17 General Principles for Planning and Design of Multiregional Clinical Trials; International Council for Harmonisation; Guidance for Industry; Availability
SUMMARY: The Food and Drug Administration is announcing the availability of a final guidance entitled "E17 General Principles for Planning and Design of Multiregional Clinical Trials." The guidance was prepared under the auspices of the International Council for Harmonisation, formerly the International Conference on Harmonisation.
7/19/18 - Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 2 Trial of Peptelligence-Engineered Oral KORSUVA?
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, congratulates Cara Therapeutics on the successful initiation of its Phase 2 clinical trial of Oral KORSUVA? in patients with pre-dialysis chronic kidney disease. Additionally, this Phase 2 initiation marks an.
7/19/18 - Evotec Receives Milestone Payment For Start Of Phase II Trial In Its Multi-Target Alliance With Bayer
HAMBURG, GERMANY/ ACCESSWIRE/ July 19, 2018/ Evotec AG, announced today that its multi- target alliance with Bayer in the field of endometriosis has advanced a promising small molecule into Phase II clinical development for the treatment of chronic cough, resulting in a payment of EUR 4 m to Evotec. The clinical Phase I trial in healthy volunteers
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415